SignalEarnings
CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates
Q3 earnings and revenues beat estimates, yet CRMD stock fell 9%.
Context
What happened: CorMedix Therapeutics $CRMD reported third-quarter 2026 results that beat estimates on adjusted loss per share and revenue, but the stock fell 8.7% after the release.
Key numbers: Adjusted loss 4 cents per share vs.
Why it matters: The decline reflected concerns over lower realized prices for DefenCath after its transition to post-TDAPA net pricing on July 1, 2026. Management deferred 2027 DefenCath revenue guidance to early 2027, citing uncertainty over quarterly Medicare reimbursement changes.
Market: -2.5% today ($28.73), +622.3% YTD, 0.3x vol — as of 17:17 UTC
Coverage: 5 outlets in 24h
What changed
CorMedix Therapeutics $CRMD reported third-quarter 2026 results that beat estimates on adjusted loss per share and revenue, but the stock fell 8.7% after the release.
Why it matters
The decline reflected concerns over lower realized prices for DefenCath after its transition to post-TDAPA net pricing on July 1, 2026. Management deferred 2027 DefenCath revenue guidance to early 2027, citing uncertainty over quarterly Medicare reimbursement changes.
Market: -2.5% today ($28.73), +622.3% YTD, 0.3x vol — as of 17:17 UTC